Pub Date : 2025-03-09DOI: 10.1016/j.jfo.2025.104473
V. Capuano , O. Semoun , A. Combes , C.-J. Mehanna , H. Oubraham , E.H. Souied
<div><div>La dégénérescence maculaire liée à l’âge (DMLA) atrophique représente une évolution défavorable de la maculopathie liée à l’âge, caractérisée par des lésions avancées de la rétine associées à des drusen, pseudodrusen ainsi qu’à des altérations de l’épithélium pigmentaire rétinien. Cette forme de DMLA se définit par un amincissement du tissu neuro-rétinien lié à la disparition des couches externes de la rétine. Notre objectif est de proposer des recommandations diagnostiques et thérapeutiques pour la prise en charge de la DMLA atrophique, à destination des ophtalmologistes, avec une approche standardisée, afin d’optimiser la gestion de cette pathologie. Le diagnostic de DMLA atrophique est fondé sur l’imagerie multimodale : la rétinographie couleur, les clichés en autofluorescence du fond d’œil (FAF) et la tomographie en cohérence optique structurelle (OCT) qui sont les examens de première intention pour évaluer la taille des lésions et l’épargne fovéolaire. L’OCT-angiographie (OCT-A) est utile afin de diagnostiquer une néovascularisation choroïdienne associée. Dans certains cas, le diagnostic différentiel peut nécessiter des examens complémentaires comme l’angiographie à la fluorescéine et/ou au vert d’indocyanine. L’évaluation de la fonction visuelle repose essentiellement sur la mesure de l’acuité visuelle. D’autres tests fonctionnels tels que la vitesse de lecture, la mesure de l’acuité visuelle en basse luminance (LLVA), la sensibilité aux contrastes ou la micropérimétrie présentent un intérêt certain, bien qu’ils ne soient pas encore utilisés en routine clinique. La prise en charge de cette pathologie est multidisciplinaire : elles nécessite une surveillance clinique régulière, un traitement médical, un soutien psychologique, une réhabilitation orthoptique et des aides visuelles optiques. Les associations de patients représentent un soutien non négligeable.</div></div><div><div>Atrophic age-related macular degeneration (AMD) represents a detrimental progression of age-related maculopathy, characterized by advanced retinal lesions associated with drusen and pseudodrusen as well as alterations in the outer retinal layers and RPE. It is characterized by a thinning of the neuroretinal tissue linked to the disappearance of the outer layers of the retina and the RPE. Our goal is to offer to ophthalmologists recommendations in the diagnosis and management of atrophic AMD with a standardized approach, in order to facilitate and optimize the management of this disease. The diagnosis of atrophic AMD is based on multimodal imaging; color fundus photography, autofluorescence images of the fundus (AFF) and structural optical coherence tomography (OCT) are the first-line examinations to assess lesion size and foveolar sparing. OCT-angiography (OCT-A) is useful in diagnosing associated choroidal neovascularization. At times, the differential diagnosis will require other complementary examinations, such as fluorescein and/or indocyanine green angi
{"title":"Approche diagnostique et parcours thérapeutique de la dégénérescence maculaire liée à l’âge de type atrophique : recommandations de la Fédération France Macula","authors":"V. Capuano , O. Semoun , A. Combes , C.-J. Mehanna , H. Oubraham , E.H. Souied","doi":"10.1016/j.jfo.2025.104473","DOIUrl":"10.1016/j.jfo.2025.104473","url":null,"abstract":"<div><div>La dégénérescence maculaire liée à l’âge (DMLA) atrophique représente une évolution défavorable de la maculopathie liée à l’âge, caractérisée par des lésions avancées de la rétine associées à des drusen, pseudodrusen ainsi qu’à des altérations de l’épithélium pigmentaire rétinien. Cette forme de DMLA se définit par un amincissement du tissu neuro-rétinien lié à la disparition des couches externes de la rétine. Notre objectif est de proposer des recommandations diagnostiques et thérapeutiques pour la prise en charge de la DMLA atrophique, à destination des ophtalmologistes, avec une approche standardisée, afin d’optimiser la gestion de cette pathologie. Le diagnostic de DMLA atrophique est fondé sur l’imagerie multimodale : la rétinographie couleur, les clichés en autofluorescence du fond d’œil (FAF) et la tomographie en cohérence optique structurelle (OCT) qui sont les examens de première intention pour évaluer la taille des lésions et l’épargne fovéolaire. L’OCT-angiographie (OCT-A) est utile afin de diagnostiquer une néovascularisation choroïdienne associée. Dans certains cas, le diagnostic différentiel peut nécessiter des examens complémentaires comme l’angiographie à la fluorescéine et/ou au vert d’indocyanine. L’évaluation de la fonction visuelle repose essentiellement sur la mesure de l’acuité visuelle. D’autres tests fonctionnels tels que la vitesse de lecture, la mesure de l’acuité visuelle en basse luminance (LLVA), la sensibilité aux contrastes ou la micropérimétrie présentent un intérêt certain, bien qu’ils ne soient pas encore utilisés en routine clinique. La prise en charge de cette pathologie est multidisciplinaire : elles nécessite une surveillance clinique régulière, un traitement médical, un soutien psychologique, une réhabilitation orthoptique et des aides visuelles optiques. Les associations de patients représentent un soutien non négligeable.</div></div><div><div>Atrophic age-related macular degeneration (AMD) represents a detrimental progression of age-related maculopathy, characterized by advanced retinal lesions associated with drusen and pseudodrusen as well as alterations in the outer retinal layers and RPE. It is characterized by a thinning of the neuroretinal tissue linked to the disappearance of the outer layers of the retina and the RPE. Our goal is to offer to ophthalmologists recommendations in the diagnosis and management of atrophic AMD with a standardized approach, in order to facilitate and optimize the management of this disease. The diagnosis of atrophic AMD is based on multimodal imaging; color fundus photography, autofluorescence images of the fundus (AFF) and structural optical coherence tomography (OCT) are the first-line examinations to assess lesion size and foveolar sparing. OCT-angiography (OCT-A) is useful in diagnosing associated choroidal neovascularization. At times, the differential diagnosis will require other complementary examinations, such as fluorescein and/or indocyanine green angi","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 4","pages":"Article 104473"},"PeriodicalIF":1.2,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-09DOI: 10.1016/j.jfo.2025.104470
M.A. Joglekar , C.M. Khare , G.A. Gadre , M.G. Dalvi , C.A. Khanwelkar
<div><h3>Objective</h3><div>To investigate and describe the clinical presentation and outcomes of a case series with possible retinal laser injury following recreational laser shows and assess their attributability to laser exposure.</div></div><div><h3>Design</h3><div>Multi-center case series.</div></div><div><h3>Subjects</h3><div>All consecutive eyes with reported laser exposure from recreational laser show and confirmed retinal injury presenting between May 2022 and April 2023.</div></div><div><h3>Methods</h3><div>Data were collected including demographics, details of laser exposure, prior ophthalmic or significant past medical history, clinical presentation including visual acuity, fundus photography, optical coherence tomography (OCT) or fundus fluorescein angiography (FFA) if available, treatment used, and follow-up and final outcomes in terms of visual acuity and complications, if any. Fundus photographs and OCT images were analyzed.</div></div><div><h3>Main outcome measures</h3><div>Demographics of the cohort, presenting and final visual acuity, morphology of retinal injury on fundus photographs and OCT images, complications if any, regression analysis to test connections to known events.</div></div><div><h3>Results</h3><div>The study included a total of 51 eyes of 51 patients, all of whom reported exposure to recreational laser shows. The mean LogMAR visual acuity at presentation was 1183 (SD 0.50). All the eyes had premacular hemorrhage of mean size 1.90 disc diameters (SD 1.29), while a dot of retinal whitening (“white spot”) was observed within the parafoveal area in 13 eyes (32.5%). Laser hyaloidotomy was performed in 54.9% of eyes, while 45.10% were managed conservatively. The majority of eyes [22, 78.57%] showed complete drainage immediately after hyaloidotomy, while partial drainage occurred in six eyes (21.43%). Only two eyes (4.26%) exhibited small residual hemorrhage at the end of the three-month period. Final mean LogMAR visual acuity was 0.123 (SD 0.20). Complications included RPE changes and epiretinal membrane formation. The incidence of cases correlated well with significant cultural events.</div></div><div><h3>Conclusion</h3><div>The presentation in all eyes was strongly suggestive of laser injury. Even though the outcomes were favorable, complications were not uncommon. We strongly recommend the immediate introduction of regulatory measures and establishment of a monitoring framework for laser shows in India. We propose referring to these injuries as “non-occupational laser exposure retinopathy”.</div></div><div><h3>Objectif</h3><div>Investiguer et décrire la présentation clinique et les résultats d’une série de cas de lésions rétiniennes possibles suite à des spectacles de laser récréatifs et évaluer leur attribuabilité à l’exposition au laser.</div></div><div><h3>Conception</h3><div>Série de cas multicentrique.</div></div><div><h3>Sujets</h3><div>Tous les yeux consécutifs présentant une exposition signalée au laser réc
{"title":"A retrospective analysis of presentation and outcomes in a cluster outbreak of non-occupational laser exposure retinopathy","authors":"M.A. Joglekar , C.M. Khare , G.A. Gadre , M.G. Dalvi , C.A. Khanwelkar","doi":"10.1016/j.jfo.2025.104470","DOIUrl":"10.1016/j.jfo.2025.104470","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate and describe the clinical presentation and outcomes of a case series with possible retinal laser injury following recreational laser shows and assess their attributability to laser exposure.</div></div><div><h3>Design</h3><div>Multi-center case series.</div></div><div><h3>Subjects</h3><div>All consecutive eyes with reported laser exposure from recreational laser show and confirmed retinal injury presenting between May 2022 and April 2023.</div></div><div><h3>Methods</h3><div>Data were collected including demographics, details of laser exposure, prior ophthalmic or significant past medical history, clinical presentation including visual acuity, fundus photography, optical coherence tomography (OCT) or fundus fluorescein angiography (FFA) if available, treatment used, and follow-up and final outcomes in terms of visual acuity and complications, if any. Fundus photographs and OCT images were analyzed.</div></div><div><h3>Main outcome measures</h3><div>Demographics of the cohort, presenting and final visual acuity, morphology of retinal injury on fundus photographs and OCT images, complications if any, regression analysis to test connections to known events.</div></div><div><h3>Results</h3><div>The study included a total of 51 eyes of 51 patients, all of whom reported exposure to recreational laser shows. The mean LogMAR visual acuity at presentation was 1183 (SD 0.50). All the eyes had premacular hemorrhage of mean size 1.90 disc diameters (SD 1.29), while a dot of retinal whitening (“white spot”) was observed within the parafoveal area in 13 eyes (32.5%). Laser hyaloidotomy was performed in 54.9% of eyes, while 45.10% were managed conservatively. The majority of eyes [22, 78.57%] showed complete drainage immediately after hyaloidotomy, while partial drainage occurred in six eyes (21.43%). Only two eyes (4.26%) exhibited small residual hemorrhage at the end of the three-month period. Final mean LogMAR visual acuity was 0.123 (SD 0.20). Complications included RPE changes and epiretinal membrane formation. The incidence of cases correlated well with significant cultural events.</div></div><div><h3>Conclusion</h3><div>The presentation in all eyes was strongly suggestive of laser injury. Even though the outcomes were favorable, complications were not uncommon. We strongly recommend the immediate introduction of regulatory measures and establishment of a monitoring framework for laser shows in India. We propose referring to these injuries as “non-occupational laser exposure retinopathy”.</div></div><div><h3>Objectif</h3><div>Investiguer et décrire la présentation clinique et les résultats d’une série de cas de lésions rétiniennes possibles suite à des spectacles de laser récréatifs et évaluer leur attribuabilité à l’exposition au laser.</div></div><div><h3>Conception</h3><div>Série de cas multicentrique.</div></div><div><h3>Sujets</h3><div>Tous les yeux consécutifs présentant une exposition signalée au laser réc","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 4","pages":"Article 104470"},"PeriodicalIF":1.2,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143580368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-08DOI: 10.1016/j.jfo.2025.104469
A.L. Mendoza-Moreira , M.T. Marcos-Parra , S. de Bari , J. Ezbakhe , E. España-Vera , M.C. Calatayud-Hernández , J.J. Pérez-Santonja
<div><h3>Purpose</h3><div>To compare iStent inject® W<!--> <!-->+<!--> <!-->phacoemulsification with XEN45 implant<!--> <!-->+<!--> <!-->phacoemulsification over 12 months in mild to moderate glaucoma patients needing cataract surgery at the Hospital General Universitario Dr. Balmis, Alicante, Spain.</div></div><div><h3>Methods</h3><div>Retrospective clinical cohort study. Consecutive patients who underwent phacoemulsification either combined with XEN45 implantation or iStent inject® W from 2020 to 2022 were included. The main outcome measure was surgical success at 12 months postoperatively. Intraocular pressure (IOP), number of antiglaucoma medications, intraoperative and postoperative complications, number of revision surgeries, use of the operating room and required visits were also evaluated.</div></div><div><h3>Results</h3><div>A total of 167 eyes were included in the study, with 101 eyes of 61 patients undergoing iStent<!--> <!-->+<!--> <!-->PHACO and 66 eyes of 46 patients undergoing XEN45<!--> <!-->+<!--> <!-->PHACO. The proportion of patients achieving a complete success (IOP<!--> <!-->≥<!--> <!-->5 and ≤ 18<!--> <!-->mmHg without medication) at the conclusion of the 12-month follow-up was 47.9% (35/73) in the iStent<!--> <!-->+<!--> <!-->PHACO and 48.2% (27/56) in the XEN45<!--> <!-->+<!--> <!-->PHACO surgery group, <em>P</em> <!-->=<!--> <!-->1.000. The mean (95% CI) IOP reduction at the conclusion of the study follow-up was –2.4 (–3.5 to –1.3<!--> <!-->mmHg, <em>P</em> <!--><<!--> <!-->0.001, iStent<!--> <!-->+<!--> <!-->PHACO) and –3.10 (–4.8 to –1.4<!--> <!-->mmHg, <em>P</em> <!--><<!--> <!-->0.001, XEN45<!--> <!-->+<!--> <!-->PHACO). The mean number of antiglaucoma medications was significantly reduced in both study groups. Rates of intraoperative complications (5 vs. 15.2%), postoperative complications (1 vs. 46.2%), reoperations (0 vs. 24.6%), mean number of operating room visits (1 vs. 1.41), and mean number of required postoperative visits (4.50 vs. 11.13) were all statistically significantly higher in the XEN45<!--> <!-->+<!--> <!-->PHACO group (< 0.001).</div></div><div><h3>Conclusions</h3><div>Both procedures achieved similar surgical success rates, with comparable reductions in IOP and the number of antiglaucoma medications. After one year, a modest IOP reduction of 10.83% was observed in the iStent group and 13.65% in the Xen group. However, the iStent inject® W demonstrated a better intraoperative and postoperative safety profile.</div></div><div><h3>Objectif</h3><div>L’objectif était de comparer l’iStent inject® W associé à une phacoémulsification avec l’implant XEN45 associé à une phacoémulsification sur une période de 12 mois chez des patients atteints de glaucome léger à modéré nécessitant une chirurgie de la cataracte à l’Hôpital General Universitario Dr Balmis, à Alicante, en Espagne.</div></div><div><h3>Méthodes</h3><div>Étude clinique rétrospective de cohorte. Des patients consécutifs ayant subi une phac
{"title":"Real-world comparison of efficacy and safety of XEN45 implant with phacoemulsification versus iStent inject® W with phacoemulsification","authors":"A.L. Mendoza-Moreira , M.T. Marcos-Parra , S. de Bari , J. Ezbakhe , E. España-Vera , M.C. Calatayud-Hernández , J.J. Pérez-Santonja","doi":"10.1016/j.jfo.2025.104469","DOIUrl":"10.1016/j.jfo.2025.104469","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare iStent inject® W<!--> <!-->+<!--> <!-->phacoemulsification with XEN45 implant<!--> <!-->+<!--> <!-->phacoemulsification over 12 months in mild to moderate glaucoma patients needing cataract surgery at the Hospital General Universitario Dr. Balmis, Alicante, Spain.</div></div><div><h3>Methods</h3><div>Retrospective clinical cohort study. Consecutive patients who underwent phacoemulsification either combined with XEN45 implantation or iStent inject® W from 2020 to 2022 were included. The main outcome measure was surgical success at 12 months postoperatively. Intraocular pressure (IOP), number of antiglaucoma medications, intraoperative and postoperative complications, number of revision surgeries, use of the operating room and required visits were also evaluated.</div></div><div><h3>Results</h3><div>A total of 167 eyes were included in the study, with 101 eyes of 61 patients undergoing iStent<!--> <!-->+<!--> <!-->PHACO and 66 eyes of 46 patients undergoing XEN45<!--> <!-->+<!--> <!-->PHACO. The proportion of patients achieving a complete success (IOP<!--> <!-->≥<!--> <!-->5 and ≤ 18<!--> <!-->mmHg without medication) at the conclusion of the 12-month follow-up was 47.9% (35/73) in the iStent<!--> <!-->+<!--> <!-->PHACO and 48.2% (27/56) in the XEN45<!--> <!-->+<!--> <!-->PHACO surgery group, <em>P</em> <!-->=<!--> <!-->1.000. The mean (95% CI) IOP reduction at the conclusion of the study follow-up was –2.4 (–3.5 to –1.3<!--> <!-->mmHg, <em>P</em> <!--><<!--> <!-->0.001, iStent<!--> <!-->+<!--> <!-->PHACO) and –3.10 (–4.8 to –1.4<!--> <!-->mmHg, <em>P</em> <!--><<!--> <!-->0.001, XEN45<!--> <!-->+<!--> <!-->PHACO). The mean number of antiglaucoma medications was significantly reduced in both study groups. Rates of intraoperative complications (5 vs. 15.2%), postoperative complications (1 vs. 46.2%), reoperations (0 vs. 24.6%), mean number of operating room visits (1 vs. 1.41), and mean number of required postoperative visits (4.50 vs. 11.13) were all statistically significantly higher in the XEN45<!--> <!-->+<!--> <!-->PHACO group (< 0.001).</div></div><div><h3>Conclusions</h3><div>Both procedures achieved similar surgical success rates, with comparable reductions in IOP and the number of antiglaucoma medications. After one year, a modest IOP reduction of 10.83% was observed in the iStent group and 13.65% in the Xen group. However, the iStent inject® W demonstrated a better intraoperative and postoperative safety profile.</div></div><div><h3>Objectif</h3><div>L’objectif était de comparer l’iStent inject® W associé à une phacoémulsification avec l’implant XEN45 associé à une phacoémulsification sur une période de 12 mois chez des patients atteints de glaucome léger à modéré nécessitant une chirurgie de la cataracte à l’Hôpital General Universitario Dr Balmis, à Alicante, en Espagne.</div></div><div><h3>Méthodes</h3><div>Étude clinique rétrospective de cohorte. Des patients consécutifs ayant subi une phac","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 4","pages":"Article 104469"},"PeriodicalIF":1.2,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143580367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-07DOI: 10.1016/j.jfo.2025.104465
V.E.W.C.M. van Renterghem, F.-X. Crahay
<div><h3>Purpose</h3><div>To compare measurements of mean keratometry (K), axial length (AL), Jackson first and second astigmatism vector (J0 and J45), astigmatism magnitude, white-to-white (WTW) diameter and anterior chamber depth (ACD) values between two biometers, the Pentacam® AXL and the IOL Master 500.</div></div><div><h3>Setting</h3><div>Public hospital in Belgium.</div></div><div><h3>Design</h3><div>Retrospective instrument reliability analysis.</div></div><div><h3>Methods</h3><div>Eyes of cataract or refractive lens exchange patients were examined preoperatively on a device combining Scheimpflug imaging and partial coherence interferometry (Pentacam® AXL) and a reference optical biometer (IOL Master 500). K, AL, J0, J45, astigmatism, WTW and ACD values were compared.</div></div><div><h3>Results</h3><div>Three hundred and twenty-eight eyes of 187 cataract or refractive lens exchange patients (mean age 68<!--> <!-->years) were examined preoperatively. Measurements of mean keratometry, axial length, ACD, white-to-white and astigmatism were significantly different (<em>P</em> <!--><<!--> <!-->0.05) between the two devices. Measurements of J0 and J45 did not significantly differ. Keratometry measurements with the Pentacam® AXL were significantly flatter than those measured with the IOL Master 500. Axial length measured with Pentacam® AXL was significantly greater when measured with the IOL Master 500, but this difference was not clinically relevant (0.015<!--> <!-->mm).</div></div><div><h3>Conclusions</h3><div>The Pentacam® AXL and the IOL Master 500 cannot be used interchangeably.</div></div><div><h3>Objectif</h3><div>Comparer les mesures de la kératométrie moyenne (K), de la longueur axiale (AL), du premier et du deuxième vecteur d’astigmatisme de Jackson (J0 et J45), de l’ampleur de l’astigmatisme, des mesures du blanc au blanc (WTW) et des valeurs de profondeur de la chambre antérieure (ACD) entre deux biomètres, le Pentacam® AXL et l’IOL Master 500.</div></div><div><h3>Lieu</h3><div>Hôpital public en Belgique.</div></div><div><h3>Conception</h3><div>Rétrospective, analyse de la fiabilité de l’instrument.</div></div><div><h3>Méthodes</h3><div>Les yeux de patients atteints de cataracte ou d’échange de lentilles réfractives ont été examinés en préopératoire sur un dispositif combinant une caméra Scheimpflug et l’interférométrie à cohérence partielle (Pentacam® AXL) et un biomètre optique de référence (IOL Master 500). Les valeurs de K, AL, J0, J45, d’astigmatisme, de WTW et d’ACD ont été comparées.</div></div><div><h3>Résultats</h3><div>Trois cent vingt-huit yeux de 187 patients ayant subi un échange de lentilles réfractives ou de cataracte (âge moyen de 68 ans) ont été examinés en préopératoire. Les mesures de la kératométrie moyenne, de la longueur axiale, de l’ACD, du blanc au blanc et de l’astigmatisme étaient significativement différentes (<em>p</em> <!--><<!--> <!-->0,05) pour les deux dispositifs. Les mesures pour J0 et J45 ne
{"title":"Biometry combining Scheimpflug imaging and partial coherence interferometry versus standard partial coherence interferometry biometry","authors":"V.E.W.C.M. van Renterghem, F.-X. Crahay","doi":"10.1016/j.jfo.2025.104465","DOIUrl":"10.1016/j.jfo.2025.104465","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare measurements of mean keratometry (K), axial length (AL), Jackson first and second astigmatism vector (J0 and J45), astigmatism magnitude, white-to-white (WTW) diameter and anterior chamber depth (ACD) values between two biometers, the Pentacam® AXL and the IOL Master 500.</div></div><div><h3>Setting</h3><div>Public hospital in Belgium.</div></div><div><h3>Design</h3><div>Retrospective instrument reliability analysis.</div></div><div><h3>Methods</h3><div>Eyes of cataract or refractive lens exchange patients were examined preoperatively on a device combining Scheimpflug imaging and partial coherence interferometry (Pentacam® AXL) and a reference optical biometer (IOL Master 500). K, AL, J0, J45, astigmatism, WTW and ACD values were compared.</div></div><div><h3>Results</h3><div>Three hundred and twenty-eight eyes of 187 cataract or refractive lens exchange patients (mean age 68<!--> <!-->years) were examined preoperatively. Measurements of mean keratometry, axial length, ACD, white-to-white and astigmatism were significantly different (<em>P</em> <!--><<!--> <!-->0.05) between the two devices. Measurements of J0 and J45 did not significantly differ. Keratometry measurements with the Pentacam® AXL were significantly flatter than those measured with the IOL Master 500. Axial length measured with Pentacam® AXL was significantly greater when measured with the IOL Master 500, but this difference was not clinically relevant (0.015<!--> <!-->mm).</div></div><div><h3>Conclusions</h3><div>The Pentacam® AXL and the IOL Master 500 cannot be used interchangeably.</div></div><div><h3>Objectif</h3><div>Comparer les mesures de la kératométrie moyenne (K), de la longueur axiale (AL), du premier et du deuxième vecteur d’astigmatisme de Jackson (J0 et J45), de l’ampleur de l’astigmatisme, des mesures du blanc au blanc (WTW) et des valeurs de profondeur de la chambre antérieure (ACD) entre deux biomètres, le Pentacam® AXL et l’IOL Master 500.</div></div><div><h3>Lieu</h3><div>Hôpital public en Belgique.</div></div><div><h3>Conception</h3><div>Rétrospective, analyse de la fiabilité de l’instrument.</div></div><div><h3>Méthodes</h3><div>Les yeux de patients atteints de cataracte ou d’échange de lentilles réfractives ont été examinés en préopératoire sur un dispositif combinant une caméra Scheimpflug et l’interférométrie à cohérence partielle (Pentacam® AXL) et un biomètre optique de référence (IOL Master 500). Les valeurs de K, AL, J0, J45, d’astigmatisme, de WTW et d’ACD ont été comparées.</div></div><div><h3>Résultats</h3><div>Trois cent vingt-huit yeux de 187 patients ayant subi un échange de lentilles réfractives ou de cataracte (âge moyen de 68 ans) ont été examinés en préopératoire. Les mesures de la kératométrie moyenne, de la longueur axiale, de l’ACD, du blanc au blanc et de l’astigmatisme étaient significativement différentes (<em>p</em> <!--><<!--> <!-->0,05) pour les deux dispositifs. Les mesures pour J0 et J45 ne ","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 4","pages":"Article 104465"},"PeriodicalIF":1.2,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-07DOI: 10.1016/j.jfo.2025.104460
E Razlog, C Arndt, A Lefevre, A Kloul
{"title":"[An attractive sea fan].","authors":"E Razlog, C Arndt, A Lefevre, A Kloul","doi":"10.1016/j.jfo.2025.104460","DOIUrl":"https://doi.org/10.1016/j.jfo.2025.104460","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-07DOI: 10.1016/j.jfo.2025.104457
H. Sener , D. Gulmez Sevim , O. Temizyurek , M.T. Uludag , F. Ozer , C. Evereklioglu , Z. Beyza Akdeniz , A.B. Gunay Sener , F. Horozoglu
<div><h3>Purpose</h3><div>To evaluate the efficacy of adalimumab (ADA) treatment in non-infectious uveitis and the effect of disease duration, age, and etiology on treatment outcome.</div></div><div><h3>Methods</h3><div>This retrospective study included patients with active non-infectious uveitis who were on ADA treatment with at least 3 months follow-up from a single tertiary care center. Uveitis type, any associated systemic disease, uveitis duration before ADA, duration of ADA treatment, best-corrected visual acuity (BCVA), anterior chamber cell (ACC) grade, vitritis grade, intraocular pressure (IOP) values, central macular thickness (CMT), fundus fluorescein angiography (FFA) score, complications and relapse rate were recorded.</div></div><div><h3>Results</h3><div>A total of 146 eyes of 77 patients (women<!--> <!-->=<!--> <!-->41, men<!--> <!-->=<!--> <!-->36) were included in the analysis. The mean age was 25.1<!--> <!-->±<!--> <!-->15.7 years. BCVA showed no significant improvement overall (+0.08, <em>P</em> <!-->=<!--> <!-->0.059) following ADA treatment. A weak negative correlation was found between the change in BCVA from baseline to final follow-up and disease duration before initiating ADA (r<!--> <!-->=<!--> <!-->−0.22, <em>P</em> <!-->=<!--> <!-->0.005). ACC and vitritis grade decreased significantly (−0.50, <em>p</em> <!--><<!--> <!-->0.001; −0.51, <em>P</em> <!--><<!--> <!-->0.001; respectively). The decrease in CMT was not significant (−18.6, <em>P</em> <!-->=<!--> <!-->0.390). Twenty patients (25.9%) experienced a relapse during treatment, and the mean relapse time was 24.9 months (95%CI: 21.0–28.9). Eleven (14.1%) of the patients required systemic corticosteroids as bridge therapy before ADA treatment and to suppress relapse while on ADA treatment. The mean dose of methylprednisolone decreased from 55.2<!--> <!-->±<!--> <!-->20.3<!--> <!-->mg to 12.3<!--> <!-->±<!--> <!-->18.0<!--> <!-->mg, and corticosteroids were discontinued in 7 of these patients.</div></div><div><h3>Conclusion</h3><div>ADA effectively controls intraocular inflammation and maintains visual stability in patients with non-infectious uveitis. Although BCVA did not show a statistically significant improvement overall, initiating ADA treatment early was correlated with better visual outcomes in some patients, particularly those who began treatment shortly after their disease onset. The corticosteroid burden was reduced.</div></div><div><h3>Objectif</h3><div>Évaluer l’efficacité du traitement par l’adalimumab (ADA) dans l’uvéite non infectieuse et l’effet de la durée de la maladie, de l’âge et de l’étiologie sur les résultats du traitement.</div></div><div><h3>Méthodes</h3><div>Cette étude rétrospective a inclus des patients atteints d’uvéite non infectieuse active sous traitement ADA avec un suivi d’au moins 3 mois dans un seul centre tertiaire. Le type d’uvéite, toute maladie systémique associée, la durée de l’uvéite avant l’ADA, la durée du traitement ADA
{"title":"Outcomes in non-infectious uveitis patients treated with adalimumab in a tertiary eye care center","authors":"H. Sener , D. Gulmez Sevim , O. Temizyurek , M.T. Uludag , F. Ozer , C. Evereklioglu , Z. Beyza Akdeniz , A.B. Gunay Sener , F. Horozoglu","doi":"10.1016/j.jfo.2025.104457","DOIUrl":"10.1016/j.jfo.2025.104457","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the efficacy of adalimumab (ADA) treatment in non-infectious uveitis and the effect of disease duration, age, and etiology on treatment outcome.</div></div><div><h3>Methods</h3><div>This retrospective study included patients with active non-infectious uveitis who were on ADA treatment with at least 3 months follow-up from a single tertiary care center. Uveitis type, any associated systemic disease, uveitis duration before ADA, duration of ADA treatment, best-corrected visual acuity (BCVA), anterior chamber cell (ACC) grade, vitritis grade, intraocular pressure (IOP) values, central macular thickness (CMT), fundus fluorescein angiography (FFA) score, complications and relapse rate were recorded.</div></div><div><h3>Results</h3><div>A total of 146 eyes of 77 patients (women<!--> <!-->=<!--> <!-->41, men<!--> <!-->=<!--> <!-->36) were included in the analysis. The mean age was 25.1<!--> <!-->±<!--> <!-->15.7 years. BCVA showed no significant improvement overall (+0.08, <em>P</em> <!-->=<!--> <!-->0.059) following ADA treatment. A weak negative correlation was found between the change in BCVA from baseline to final follow-up and disease duration before initiating ADA (r<!--> <!-->=<!--> <!-->−0.22, <em>P</em> <!-->=<!--> <!-->0.005). ACC and vitritis grade decreased significantly (−0.50, <em>p</em> <!--><<!--> <!-->0.001; −0.51, <em>P</em> <!--><<!--> <!-->0.001; respectively). The decrease in CMT was not significant (−18.6, <em>P</em> <!-->=<!--> <!-->0.390). Twenty patients (25.9%) experienced a relapse during treatment, and the mean relapse time was 24.9 months (95%CI: 21.0–28.9). Eleven (14.1%) of the patients required systemic corticosteroids as bridge therapy before ADA treatment and to suppress relapse while on ADA treatment. The mean dose of methylprednisolone decreased from 55.2<!--> <!-->±<!--> <!-->20.3<!--> <!-->mg to 12.3<!--> <!-->±<!--> <!-->18.0<!--> <!-->mg, and corticosteroids were discontinued in 7 of these patients.</div></div><div><h3>Conclusion</h3><div>ADA effectively controls intraocular inflammation and maintains visual stability in patients with non-infectious uveitis. Although BCVA did not show a statistically significant improvement overall, initiating ADA treatment early was correlated with better visual outcomes in some patients, particularly those who began treatment shortly after their disease onset. The corticosteroid burden was reduced.</div></div><div><h3>Objectif</h3><div>Évaluer l’efficacité du traitement par l’adalimumab (ADA) dans l’uvéite non infectieuse et l’effet de la durée de la maladie, de l’âge et de l’étiologie sur les résultats du traitement.</div></div><div><h3>Méthodes</h3><div>Cette étude rétrospective a inclus des patients atteints d’uvéite non infectieuse active sous traitement ADA avec un suivi d’au moins 3 mois dans un seul centre tertiaire. Le type d’uvéite, toute maladie systémique associée, la durée de l’uvéite avant l’ADA, la durée du traitement ADA","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 4","pages":"Article 104457"},"PeriodicalIF":1.2,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-07DOI: 10.1016/j.jfo.2025.104467
R. Selimoğlu, A. Mete, S.A. Seyyar, S. Kimyon
<div><h3>Purpose</h3><div>To compare the serum lipid profile and 25-hydroxyvitamin D3 (25-OH D3) levels of patients diagnosed with obstructive meibomian gland dysfunction (OMGD) and healthy controls.</div></div><div><h3>Methods</h3><div>This prospective study included OMGD patients who were seen at our clinic between April 2023 and October 2023 and age- and gender-matched controls. All participants underwent a detailed ophthalmological examination, including Ocular Surface Disease Index (OSDI) testing, tear-film breakup time (TBUT), and shrinkage testing. Ocular surface staining (corneal and conjunctival staining) was evaluated according to the Oxford scale. The quality of the main meibomian secretions, morphological differences at the lid margin, and the degree of contamination of the meibomian secretions, which directly indicates meiboimian gland dysfunction, were evaluated. Serum 25-OH D3, triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels were compared.</div></div><div><h3>Results</h3><div>Of our participants, 35 OMGD patients and 35 healthy controls, 35 (50%) were female and 35 (50%) were male. No statistically significant difference was observed in vitamin D levels between the healthy and OMGD groups (<em>P</em> <!-->=<!--> <!-->0.112). There was no significant difference in the distribution of serum vitamin D levels (deficient, inadequate, and optimal) between the two groups (<em>P</em> <!-->><!--> <!-->0.05). Serum lipid levels (TG, TC, HDL, and LDL) were higher in the OMGD group than in the control group, but only TG was statistically significant (<em>P</em> <!-->=<!--> <!-->0.001).</div></div><div><h3>Conclusion</h3><div>Serum vitamin D levels did not significantly differ between the OMGD and control groups. However, there may be a relationship between the serum lipid profile and OMGD.</div></div><div><h3>Objectif</h3><div>Comparer le profil lipidique sérique et les taux de 25-hydroxyvitamine D (25-OH D3) de patients diagnostiqués avec un dysfonctionnement obstructif des glandes de Meibomius (OMGD) et de témoins sains.</div></div><div><h3>Méthodes</h3><div>Cette étude prospective a inclus des patients atteints d’OMGD qui ont postulé à notre clinique entre avril 2023 et octobre 2023, et des témoins appariés selon l’âge et le sexe. Tous les participants ont subi un examen ophtalmologique détaillé, comprenant un test de l’indice de dommage de la surface oculaire (OSDI), un temps de rupture des larmes (TBUT) et un test de rétrécissement. La coloration de la surface oculaire (coloration de la cornée et de la conjonctive) a été évaluée selon l’échelle d’Oxford. La qualité de la sécrétion meibomienne principale, les différences morphologiques au niveau du bord de la paupière et le degré de contamination de la sécrétion meibomienne, qui indique directement un dysfonctionnement des glandes de Meibomius, ont été évalués. Les taux sériques de 25-OH D3, de triglycérides (TG), de lipoprotéines de basse den
{"title":"Evaluation of vitamin D and serum lipid profile levels in obstructive meibomian gland dysfunction","authors":"R. Selimoğlu, A. Mete, S.A. Seyyar, S. Kimyon","doi":"10.1016/j.jfo.2025.104467","DOIUrl":"10.1016/j.jfo.2025.104467","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare the serum lipid profile and 25-hydroxyvitamin D3 (25-OH D3) levels of patients diagnosed with obstructive meibomian gland dysfunction (OMGD) and healthy controls.</div></div><div><h3>Methods</h3><div>This prospective study included OMGD patients who were seen at our clinic between April 2023 and October 2023 and age- and gender-matched controls. All participants underwent a detailed ophthalmological examination, including Ocular Surface Disease Index (OSDI) testing, tear-film breakup time (TBUT), and shrinkage testing. Ocular surface staining (corneal and conjunctival staining) was evaluated according to the Oxford scale. The quality of the main meibomian secretions, morphological differences at the lid margin, and the degree of contamination of the meibomian secretions, which directly indicates meiboimian gland dysfunction, were evaluated. Serum 25-OH D3, triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels were compared.</div></div><div><h3>Results</h3><div>Of our participants, 35 OMGD patients and 35 healthy controls, 35 (50%) were female and 35 (50%) were male. No statistically significant difference was observed in vitamin D levels between the healthy and OMGD groups (<em>P</em> <!-->=<!--> <!-->0.112). There was no significant difference in the distribution of serum vitamin D levels (deficient, inadequate, and optimal) between the two groups (<em>P</em> <!-->><!--> <!-->0.05). Serum lipid levels (TG, TC, HDL, and LDL) were higher in the OMGD group than in the control group, but only TG was statistically significant (<em>P</em> <!-->=<!--> <!-->0.001).</div></div><div><h3>Conclusion</h3><div>Serum vitamin D levels did not significantly differ between the OMGD and control groups. However, there may be a relationship between the serum lipid profile and OMGD.</div></div><div><h3>Objectif</h3><div>Comparer le profil lipidique sérique et les taux de 25-hydroxyvitamine D (25-OH D3) de patients diagnostiqués avec un dysfonctionnement obstructif des glandes de Meibomius (OMGD) et de témoins sains.</div></div><div><h3>Méthodes</h3><div>Cette étude prospective a inclus des patients atteints d’OMGD qui ont postulé à notre clinique entre avril 2023 et octobre 2023, et des témoins appariés selon l’âge et le sexe. Tous les participants ont subi un examen ophtalmologique détaillé, comprenant un test de l’indice de dommage de la surface oculaire (OSDI), un temps de rupture des larmes (TBUT) et un test de rétrécissement. La coloration de la surface oculaire (coloration de la cornée et de la conjonctive) a été évaluée selon l’échelle d’Oxford. La qualité de la sécrétion meibomienne principale, les différences morphologiques au niveau du bord de la paupière et le degré de contamination de la sécrétion meibomienne, qui indique directement un dysfonctionnement des glandes de Meibomius, ont été évalués. Les taux sériques de 25-OH D3, de triglycérides (TG), de lipoprotéines de basse den","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 4","pages":"Article 104467"},"PeriodicalIF":1.2,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-07DOI: 10.1016/j.jfo.2025.104464
L Hamoudi, S Tan, A Grare, P Labalette
{"title":"[Retinal detachment with giant retinal tear in high myopia patient].","authors":"L Hamoudi, S Tan, A Grare, P Labalette","doi":"10.1016/j.jfo.2025.104464","DOIUrl":"https://doi.org/10.1016/j.jfo.2025.104464","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-06DOI: 10.1016/j.jfo.2025.104471
V Maréchal, E Bruyère, A Mière, E Souied
{"title":"[Spontaneous resolution of foveoschisis secondary to intravitreal ranibizumab injection for myopic choroidal neovascularization].","authors":"V Maréchal, E Bruyère, A Mière, E Souied","doi":"10.1016/j.jfo.2025.104471","DOIUrl":"https://doi.org/10.1016/j.jfo.2025.104471","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1016/j.jfo.2025.104463
C Khodriss, E Firdaous Essaddouqui, M El Bahloul
{"title":"Leaf-like grouping of epicapsular stars.","authors":"C Khodriss, E Firdaous Essaddouqui, M El Bahloul","doi":"10.1016/j.jfo.2025.104463","DOIUrl":"https://doi.org/10.1016/j.jfo.2025.104463","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：